Sorafenib inhibits tumor angiogenesis by targeting Raf serine/threonine kinases, besides different receptor tyrosine kinases, including c-Kit, FLT-3, vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) signaling10. Here, VEGFA is linked to neoplasm.